<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
   <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
         <publisher-name>Public Library of Science</publisher-name>
         <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
   <article-meta><article-id pub-id-type="publisher-id">10-PLCB-RA-2776R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1001072</article-id><article-categories>
         <subj-group subj-group-type="heading">
            <subject>Research Article</subject>
         </subj-group>
         <subj-group subj-group-type="Discipline">
<subject>Computational Biology</subject>
<subject>Hematology/Anemias</subject>
<subject>Infectious Diseases/Viral Infections</subject>
<subject>Mathematics</subject>
<subject>Pharmacology/Adverse Reactions</subject>
         </subj-group>
      </article-categories><title-group><article-title>Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy</article-title><alt-title alt-title-type="running-head">Ribavirin-Induced Anemia</alt-title></title-group><contrib-group>
         <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western"><surname>Krishnan</surname><given-names>Sheeja M.</given-names></name>
            <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
         </contrib>
         <contrib contrib-type="author" xlink:type="simple">
            <name name-style="western"><surname>Dixit</surname><given-names>Narendra M.</given-names></name>
            <xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
            <xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
            <xref ref-type="corresp" rid="cor1"><sup>*</sup></xref>
         </contrib>
      </contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Chemical Engineering, Indian Institute of Science, Bangalore, India</addr-line>
      </aff><aff id="aff2"><label>2</label><addr-line>Bioinformatics Centre, Indian Institute of Science, Bangalore, India</addr-line>
      </aff><contrib-group>
         <contrib contrib-type="editor" xlink:type="simple">
            <name name-style="western"><surname>Antia</surname><given-names>Rustom</given-names></name>
            <role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib>
      </contrib-group><aff id="edit1">Emory University, United States of America</aff><author-notes>
         <corresp id="cor1">* E-mail: <email xlink:type="simple">narendra@chemeng.iisc.ernet.in</email></corresp>
         <fn fn-type="con">
            <p>Conceived and designed the experiments: SMK NMD. Performed the experiments: SMK. Analyzed the data: SMK NMD. Contributed reagents/materials/analysis tools: SMK NMD. Wrote the paper: SMK NMD.</p>
         </fn>
      <fn fn-type="conflict">
         <p>The authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
         <month>2</month>
         <year>2011</year>
      </pub-date><pub-date pub-type="epub">
         <day>3</day>
         <month>2</month>
         <year>2011</year>
      </pub-date><volume>7</volume><issue>2</issue><elocation-id>e1001072</elocation-id><history>
         <date date-type="received">
            <day>30</day>
            <month>8</month>
            <year>2010</year>
         </date>
         <date date-type="accepted">
            <day>29</day>
            <month>12</month>
            <year>2010</year>
         </date>
      </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Krishnan, Dixit</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
         <p>The current standard of care for hepatitis C virus (HCV) infection – combination therapy with pegylated interferon and ribavirin – elicits sustained responses in only ∼50% of the patients treated. No alternatives exist for patients who do not respond to combination therapy. Addition of ribavirin substantially improves response rates to interferon and lowers relapse rates following the cessation of therapy, suggesting that increasing ribavirin exposure may further improve treatment response. A key limitation, however, is the toxic side-effect of ribavirin, hemolytic anemia, which often necessitates a reduction of ribavirin dosage and compromises treatment response. Maximizing treatment response thus requires striking a balance between the antiviral and hemolytic activities of ribavirin. Current models of viral kinetics describe the enhancement of treatment response due to ribavirin. Ribavirin-induced anemia, however, remains poorly understood and precludes rational optimization of combination therapy. Here, we develop a new mathematical model of the population dynamics of erythrocytes that quantitatively describes ribavirin-induced anemia in HCV patients. Based on the assumption that ribavirin accumulation decreases erythrocyte lifespan in a dose-dependent manner, model predictions capture several independent experimental observations of the accumulation of ribavirin in erythrocytes and the resulting decline of hemoglobin in HCV patients undergoing combination therapy, estimate the reduced erythrocyte lifespan during therapy, and describe inter-patient variations in the severity of ribavirin-induced anemia. Further, model predictions estimate the threshold ribavirin exposure beyond which anemia becomes intolerable and suggest guidelines for the usage of growth hormones, such as erythropoietin, that stimulate erythrocyte production and avert the reduction of ribavirin dosage, thereby improving treatment response. Our model thus facilitates, in conjunction with models of viral kinetics, the rational identification of treatment protocols that maximize treatment response while curtailing side effects.</p>
      </abstract><abstract abstract-type="summary">
         <title>Author Summary</title>
         <p>The treatment of HCV infection poses a major global health-care challenge today. The current standard of care, combination therapy with interferon and ribavirin, works in only about half of the patients treated. Because no alternatives are available yet for patients in whom combination therapy fails, identifying ways to improve response to combination therapy is critical. Increasing exposure to ribavirin does improve response but is associated with the severe side-effect, anemia. One way to maximize treatment response therefore is to increase ribavirin exposure to levels just below where anemia becomes intolerable. A second way is to supplement combination therapy with growth hormones, such as erythropoietin, that increase the production of red blood cells (erythrocytes) and compensate for ribavirin-induced anemia. Rational optimization of combination therapy thus relies on a quantitative description of ribavirin-induced anemia, which is currently lacking. Here, we develop a model of the population dynamics of erythrocytes in individuals exposed to ribavirin that quantitatively describes ribavirin-induced anemia. Model predictions capture several independent observations of ribavirin-induced anemia in HCV patients undergoing combination therapy, estimate the threshold ribavirin exposure beyond which anemia becomes intolerable, suggest guidelines for the usage of growth hormones, and facilitate rational optimization of therapy.</p>
      </abstract><funding-group><funding-statement>This work was supported by the Department of Biotechnology Centre of Excellence for Research on Hepatitis C Virus, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts>
<page-count count="10"/>
</counts></article-meta>
</front>
<body>
   <sec id="s1">
      <title>Introduction</title>
      <p>130–170 million people worldwide are currently infected with hepatitis C virus (HCV) <xref ref-type="bibr" rid="pcbi.1001072-Lavanchy1">[1]</xref>. Over 70% of HCV infections become chronic and if untreated may lead to cirrhosis and hepatocellular carcinoma, necessitating liver transplantation <xref ref-type="bibr" rid="pcbi.1001072-Lavanchy1">[1]</xref>. The standard of care for HCV infection involves combination therapy with pegylated interferon and ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Ghany1">[2]</xref>. Ribavirin alone does not elicit a lasting antiviral response <xref ref-type="bibr" rid="pcbi.1001072-Dusheiko1">[3]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Pawlotsky1">[6]</xref>, yet it substantially improves treatment response in combination with interferon <xref ref-type="bibr" rid="pcbi.1001072-Manns1">[7]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Poynard1">[11]</xref>. For instance, whereas ∼29% of the patients treated with interferon exhibited a sustained virological response (SVR), the response rate increased to ∼56% upon addition of ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Fried1">[8]</xref>. Ribavirin, however, is associated with the side-effect, hemolytic anemia, which often renders therapy intolerable <xref ref-type="bibr" rid="pcbi.1001072-Bodenheimer1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Franceschi1">[12]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Sulkowski2">[15]</xref>. With the standard ribavirin dosage of 1000–1200 mg/day, 54% of the patients treated experienced a decline in the hemoglobin (Hb) level of over 3 g/dL, and 10% of the men and 7% of the women treated experienced an Hb decline of over 5 g/dL (normal Hb range: 14–16 g/dL) <xref ref-type="bibr" rid="pcbi.1001072-Sulkowski2">[15]</xref>. This drop in Hb often necessitates a reduction of ribavirin dosage, which significantly compromises treatment response <xref ref-type="bibr" rid="pcbi.1001072-Manns1">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Sulkowski1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Reddy1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Reddy2">[16]</xref>. The probability of achieving SVR is estimated to decrease from ∼65% to ∼45% when ribavirin dosage is reduced from ∼15 mg/kg to ∼7 mg/kg of body weight, in combination with pegylated interferon at 1.5 µg/kg of body weight <xref ref-type="bibr" rid="pcbi.1001072-Manns1">[7]</xref>. Patients receiving fewer than 60% of the planned ribavirin doses had lower response rates <xref ref-type="bibr" rid="pcbi.1001072-Reddy1">[14]</xref>, indicating that lower cumulative ribavirin exposure results in poorer treatment response <xref ref-type="bibr" rid="pcbi.1001072-Sulkowski1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Reddy2">[16]</xref>. The rates of relapse of infection following the end of treatment also increased upon lowering ribavirin dosage <xref ref-type="bibr" rid="pcbi.1001072-Reddy1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Reddy2">[16]</xref>. In a recent clinical trial where interferon was employed with telaprevir, a promising new inhibitor of HCV protease, response rates were lowest in patients who were not administered ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Hazode1">[17]</xref>, underscoring the importance of ribavirin in achieving SVR.</p>
      <p>Alternatives for patients who do not respond to combination therapy do not exist yet <xref ref-type="bibr" rid="pcbi.1001072-Ghany1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Lemon1">[18]</xref>. Significant efforts are underway therefore to identify treatment protocols that maximize response rates to combination therapy while curtailing side-effects <xref ref-type="bibr" rid="pcbi.1001072-Reddy2">[16]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Zeuzem1">[19]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-DebRoy1">[25]</xref>. A particularly promising strategy is to supplement combination therapy with growth hormones, such as erythropoietin, that stimulate erythropoiesis and thus avert the reduction of ribavirin dosage, potentially improving treatment response <xref ref-type="bibr" rid="pcbi.1001072-Dieterich1">[26]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Falasca1">[31]</xref>. The predominant mechanism(s) of the anti-HCV activity of ribavirin remain to be established <xref ref-type="bibr" rid="pcbi.1001072-Feld1">[32]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Dixit1">[34]</xref>. Mathematical models of viral kinetics have been developed that describe the antiviral activity of interferon and the enhancement of treatment response rates due to ribavirin, and are being extended to predict the impact of new antiviral drugs <xref ref-type="bibr" rid="pcbi.1001072-Dixit1">[34]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Rong2">[42]</xref>. Ribavirin-induced anemia, on the other hand, remains poorly understood <xref ref-type="bibr" rid="pcbi.1001072-Sulkowski1">[13]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Tod1">[24]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-DebRoy1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Vlierberghe1">[43]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref> and precludes rational optimization of combination therapy.</p>
      <p>Here, we construct a mathematical model of the population dynamics of erythrocytes that quantitatively describes ribavirin-induced anemia and informs future strategies for improving outcomes of combination therapy. Model predictions capture experimental observations of the accumulation of ribavirin in erythrocytes and the ensuing Hb decline in HCV patients following the onset of combination therapy, estimate the enhanced turnover rate of erythrocytes during therapy and the threshold ribavirin exposure beyond which anemia is intolerable, present guidelines for the optimal usage of growth hormone supplements, and provide a framework, in conjunction with models of viral kinetics, for rational optimization of combination therapy.</p>
   </sec>
   <sec id="s2">
      <title>Results</title>
      <sec id="s2a">
         <title>Model formulation</title>
         <p>Prior to the onset of treatment with ribavirin, the population of erythrocytes (RBCs) in an HCV infected individual is constant; a balance exists between RBC production and death (<xref ref-type="fig" rid="pcbi-1001072-g001">Fig. 1</xref>). Following the onset of treatment, ribavirin administered orally gets rapidly transported from the plasma to RBCs, where it is phosphorylated to its mono-, di- and tri-phosphate analogs (RMP, RDP, and RTP) <xref ref-type="bibr" rid="pcbi.1001072-Glue1">[48]</xref>. Phosphorylated analogs are neither easily metabolized nor transported out of RBCs <xref ref-type="bibr" rid="pcbi.1001072-Glue1">[48]</xref>. Consequently, ribavirin accumulates inside RBCs in the form of its phosphorylated analogs; the total intracellular concentration of ribavirin can be &gt;100-fold its extracellular concentration <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref>. This dramatic accumulation of ribavirin may induce oxidative damage and result in enhanced extra vascular death of RBCs <xref ref-type="bibr" rid="pcbi.1001072-Franceschi1">[12]</xref>. Indeed, RBC lifespan decreased from 107±22 d in HCV patients not exposed to ribavirin to 39±13 d in HCV patients undergoing treatment with ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Krishnan1">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Virtue1">[50]</xref>. The shortened RBC lifespan creates an imbalance between RBC production and death and results in a decline in the RBC population. Accordingly, Hb levels drop and patients become anemic. We construct a mathematical model to describe this dynamics of ribavirin-induced anemia (<xref ref-type="sec" rid="s4">Methods</xref>).</p>
         <fig id="pcbi-1001072-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001072.g001</object-id><label>Figure 1</label>
            <caption>
               <title>Schematic of the population dynamics of RBCs in HCV infected individuals.</title>
               <p><bold>A</bold>, Before the onset of combination therapy, the production and death rates of RBCs are balanced and the population of RBCs in plasma is constant. <bold>B</bold>, Following the onset of therapy, ribavirin enters RBCs and increases their death rates. Cells born at different times are exposed to ribavirin for different durations and hence carry different concentrations of ribavirin. The enhanced death rate lowers the RBC population, which triggers an increase in the RBC production from the bone marrow by a negative feedback through the hormone erythropoietin.</p>
            </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.g001" xlink:type="simple"/></fig>
      </sec>
      <sec id="s2b">
         <title>Model predictions</title>
         <sec id="s2b1">
            <title>Population dynamics of RBCs during treatment with ribavirin</title>
            <p>We present model predictions in terms of the cumulative population, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e001" xlink:type="simple"/></inline-formula>, which is the population of RBCs at time <italic>t</italic> following the onset of treatment in which the concentration of ribavirin phosphorylated analogs, RXP, is less than or equal to <italic>C</italic> (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2A</xref>). (RXP comprises RMP, RDP, and RTP.) At the start of treatment <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e002" xlink:type="simple"/></inline-formula>, no cells contain RXP, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e003" xlink:type="simple"/></inline-formula> for all <italic>C</italic>, where <italic>N</italic><sub>0</sub> is the steady population of RBCs prior to the onset of treatment. In other words, the population of cells carrying RXP at concentrations smaller than or equal to <italic>C</italic> is <italic>N</italic><sub>0</sub> for all <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e004" xlink:type="simple"/></inline-formula>. At <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e005" xlink:type="simple"/></inline-formula>, the production and death rates of RBCs are in balance (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2B</xref>), the hemoglobin level, <italic>Hb</italic> = <italic>Hb</italic><sub>0</sub>, and the average intracellular concentration of ribavirin, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e006" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2C</xref>). With time, ribavirin accumulates inside cells. At any time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e007" xlink:type="simple"/></inline-formula>, a distribution of RXP concentrations across cells emerges with cells exposed to ribavirin longer possessing higher concentrations of RXP. Thus, cells present from the start of treatment possess the highest concentration of RXP. At <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e008" xlink:type="simple"/></inline-formula> d, for instance, the latter cells possess RXP at the concentration <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e009" xlink:type="simple"/></inline-formula>, where <italic>C</italic><sub>max</sub> = <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e010" xlink:type="simple"/></inline-formula> is the maximum intracellular concentration of RXP for a given extracellular concentration of ribavirin <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e011" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2A</xref>). Cells born after the onset of treatment possess RXP at concentrations smaller than <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e012" xlink:type="simple"/></inline-formula> at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e013" xlink:type="simple"/></inline-formula> d. Because most of the cells present at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e014" xlink:type="simple"/></inline-formula> d are from the population that existed at the start of therapy, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e015" xlink:type="simple"/></inline-formula> exhibits a sharp rise at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e016" xlink:type="simple"/></inline-formula> and reaches the value <italic>N</italic>(<italic>t</italic> = 1) (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2A</xref>). With time, the sharp rise in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e017" xlink:type="simple"/></inline-formula> shifts to higher values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e018" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2A</xref>) indicating greater accumulation of RXP. Accordingly, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e019" xlink:type="simple"/></inline-formula> increases (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2C</xref>). Cells die at increasing rates as intracellular RXP accumulates (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2B</xref>). The population of RBCs, <italic>N</italic>(<italic>t</italic>), and, hence, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e020" xlink:type="simple"/></inline-formula> correspondingly decrease (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2C</xref>). New cells are continuously produced at a rate that increases as the RBC population declines (<xref ref-type="fig" rid="pcbi-1001072-g002">Fig. 2B</xref>). Eventually, a new balance between RBC production and death is attained, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e021" xlink:type="simple"/></inline-formula> reaches a steady distribution, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e022" xlink:type="simple"/></inline-formula> reaches an asymptotic maximum <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e023" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e024" xlink:type="simple"/></inline-formula> attains a new, lower steady value <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e025" xlink:type="simple"/></inline-formula>.</p>
            <fig id="pcbi-1001072-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001072.g002</object-id><label>Figure 2</label>
               <caption>
                  <title>Model predictions of the dynamics of ribavirin-induced anemia.</title>
                  <p><bold>A</bold>, The cumulative population, <italic>m</italic>(<italic>C</italic>,<italic>t</italic>), of RBCs as a function of the intracellular concentration of RXP, <italic>C</italic>, at different times, <italic>t</italic>, following the onset of combination therapy, predicted by Eqs. (1)–(3). Parameters employed are listed in <xref ref-type="table" rid="pcbi-1001072-t001">Table 1</xref>. <italic>m</italic>(<italic>C</italic>,<italic>t</italic>) is normalized by <italic>N</italic><sub>0</sub> and <italic>C</italic> by <italic>C</italic><sub>max</sub> = <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e026" xlink:type="simple"/></inline-formula>. <bold>B</bold>, The production rate, <italic>P</italic>(<italic>t</italic>), and the death rate <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e027" xlink:type="simple"/></inline-formula> of RBCs. <bold>C</bold>, The corresponding change in <italic>Hb</italic> (red) and <italic>C</italic><sub>avg</sub> (green).</p>
               </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.g002" xlink:type="simple"/></fig>
         </sec>
         <sec id="s2b2">
            <title>Factors that influence the severity of ribavirin-induced anemia</title>
            <p>An increase in the steady state plasma concentration of ribavirin, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e028" xlink:type="simple"/></inline-formula>, which may be achieved with a higher dosage, results in an increase in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e029" xlink:type="simple"/></inline-formula> and a decrease in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e030" xlink:type="simple"/></inline-formula>, illustrating the more severe anemia that results with increased ribavirin exposure. For instance, increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e031" xlink:type="simple"/></inline-formula> from 5 µM to 15 µM increases the total drop in <italic>Hb</italic>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e032" xlink:type="simple"/></inline-formula>, from ∼2 g/dL to ∼5 g/dL (<xref ref-type="fig" rid="pcbi-1001072-g003">Fig. 3A</xref>). An increase in the intracellular phosphorylation rate, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e033" xlink:type="simple"/></inline-formula>, (or a decrease in the loss rate of intracellular RXP, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e034" xlink:type="simple"/></inline-formula>) results in a higher <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e035" xlink:type="simple"/></inline-formula> for the same <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e036" xlink:type="simple"/></inline-formula>, which in turn elevates cell death rates and lowers <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e037" xlink:type="simple"/></inline-formula>. Thus, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e038" xlink:type="simple"/></inline-formula> increases from ∼2.5 g/dL when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e039" xlink:type="simple"/></inline-formula> d<sup>−1</sup> to ∼3.5 g/dL when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e040" xlink:type="simple"/></inline-formula> d<sup>−1</sup> (<xref ref-type="fig" rid="pcbi-1001072-g003">Fig. 3B</xref>), illustrating that differences in the intracellular metabolism of ribavirin may contribute to inter-patient variations in the severity of ribavirin-induced anemia. Enhancing the RBC production rate, by increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e041" xlink:type="simple"/></inline-formula> (see Eq. (3)), (or lowering the sensitivity of the RBC death rate to ribavirin accumulation, by increasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e042" xlink:type="simple"/></inline-formula> or decreasing <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e043" xlink:type="simple"/></inline-formula> (see Eq. (2))), reduces <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e044" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1001072-g003">Fig. 3C</xref>). Administration of growth hormones, such as erythropoietin, enhances the RBC production rate, which reduces <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e045" xlink:type="simple"/></inline-formula> for the same ribavirin exposure and thus improves the tolerability of ribavirin. Similarly, decrease in the intracellular inosine triphosphatase level, observed recently in some patients <xref ref-type="bibr" rid="pcbi.1001072-Fellay1">[51]</xref>, may interfere with RTP activity and lower the sensitivity of the RBC death rate to ribavirin, which also reduces <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e046" xlink:type="simple"/></inline-formula> and improves the tolerability of ribavirin.</p>
            <fig id="pcbi-1001072-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001072.g003</object-id><label>Figure 3</label>
               <caption>
                  <title>Factors influencing the dynamics of ribavirin-induced anemia.</title>
                  <p>Changes in <italic>Hb</italic> (red) and <italic>C</italic><sub>avg</sub> (green) predicted by Eqs. (1)–(3) for different parameter values: <bold>A</bold>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e047" xlink:type="simple"/></inline-formula>5 µM (solid lines), 10 µM (dashed lines) and 15 µM (dotted lines). <bold>B</bold>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e048" xlink:type="simple"/></inline-formula> (solid lines), 65 d<sup>−1</sup> (dashed lines), 80 d<sup>−1</sup> (dotted lines). <bold>C</bold>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e049" xlink:type="simple"/></inline-formula> (solid lines), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e050" xlink:type="simple"/></inline-formula> (dashed lines), <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e051" xlink:type="simple"/></inline-formula> (dotted lines). The other parameters are mentioned in <xref ref-type="table" rid="pcbi-1001072-t001">Table 1</xref>.</p>
               </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.g003" xlink:type="simple"/></fig>
         </sec>
         <sec id="s2b3">
            <title>Inter-patient variations</title>
            <p>Inter-patient variability in the severity of anemia may arise from variations in the intracellular uptake, accumulation, or metabolism of ribavirin, as well as in the dependence of the RBC lifespan on ribavirin accumulation and in the sensitivity of the RBC production rate to changes in <italic>Hb</italic>. To obtain a measure of this inter-patient variability, we calculated <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e052" xlink:type="simple"/></inline-formula> using 500 different combinations of the values of the parameters, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e053" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e054" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e055" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e056" xlink:type="simple"/></inline-formula>, for a range of values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e057" xlink:type="simple"/></inline-formula>. The parameter values for each combination were chosen randomly from Gaussian distributions based on the mean values and confidence levels of the respective parameters obtained from comparisons of our model predictions with patient data (see below). Indeed, we find that inter-patient variations in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e058" xlink:type="simple"/></inline-formula> may be substantial for any ribavirin exposure (<xref ref-type="fig" rid="pcbi-1001072-g004">Fig. 4A</xref>) or intracellular accumulation (<xref ref-type="fig" rid="pcbi-1001072-g004">Fig. 4B</xref>). Further, the variation increases with increase in ribavirin exposure and intracellular accumulation.</p>
            <fig id="pcbi-1001072-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001072.g004</object-id><label>Figure 4</label>
               <caption>
                  <title>Model predictions of the variations in the severity of ribavirin-induced anemia.</title>
                  <p>The reduction in <italic>Hb</italic> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e059" xlink:type="simple"/></inline-formula>) predicted by Eqs. (1)–(3) as a function of <bold>A</bold>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e060" xlink:type="simple"/></inline-formula>, and <bold>B</bold>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e061" xlink:type="simple"/></inline-formula>, for 500 different combinations of the parameter values (mean±s.d.) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e062" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e063" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e064" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e065" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e066" xlink:type="simple"/></inline-formula>. The standard deviations on the parameter values correspond to the 95% confidence limits obtained from the best-fits to patient data (see <xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5</xref>). The other parameters are mentioned in <xref ref-type="table" rid="pcbi-1001072-t001">Table 1</xref>.</p>
               </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.g004" xlink:type="simple"/></fig>
            <p>Below, we compare our model predictions with experiments.</p>
         </sec>
      </sec>
      <sec id="s2c">
         <title>Comparisons of model predictions with patient data</title>
         <p>We consider a recent study of the time-evolution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e067" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e068" xlink:type="simple"/></inline-formula> in 19 Japanese patients following the onset of combination therapy <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref>. In this latter study, no reduction of ribavirin dosage is reported. The patients were divided into two groups based on whether <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e069" xlink:type="simple"/></inline-formula>&lt;1000 µM (7 patients) or <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e070" xlink:type="simple"/></inline-formula>&gt;1000 µM (12 patients); the data are reported as the average within each group. We fit model predictions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e071" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e072" xlink:type="simple"/></inline-formula> to the data of the former 7 patients using <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e073" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e074" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e075" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e076" xlink:type="simple"/></inline-formula> as adjustable parameters. (Interferon may also induce anemia, but does so to a much smaller extent than ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Sulkowski1">[13]</xref>. We therefore assume that the <italic>Hb</italic> decline in patients undergoing combination therapy is primarily due to ribavirin.) We fix the remaining parameters based on previous studies or from analysis of independent experiments (<xref ref-type="sec" rid="s4">Methods</xref>). Model predictions provide good fits to the data and yield estimates of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e077" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e078" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e079" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e080" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5A</xref>). The fits suggest that our model is able to describe the underlying dynamics of ribavirin-induced anemia in HCV patients.</p>
         <fig id="pcbi-1001072-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001072.g005</object-id><label>Figure 5</label>
            <caption>
               <title>Comparisons of model predictions with experiments.</title>
               <p><bold>A</bold>, Best-fits of model predictions (lines) of <italic>Hb</italic> (red) and <italic>C</italic><sub>avg</sub> (green) with experimental data (symbols) from 7 Japanese patients with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e081" xlink:type="simple"/></inline-formula>&lt;1000 µM <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref>. We let <italic>Hb</italic><sub>0</sub> = 14.4 g/dL and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e082" xlink:type="simple"/></inline-formula> following the mean reported values for these patients <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref>. We use <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e083" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e084" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e085" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e086" xlink:type="simple"/></inline-formula> as adjustable parameters. The remaining parameters are mentioned in <xref ref-type="table" rid="pcbi-1001072-t001">Table 1</xref>. The resulting best-fit parameter estimates (95% CI) are <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e087" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e088" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e089" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e090" xlink:type="simple"/></inline-formula>. Dashed lines show 95% confidence intervals on the predictions. <bold>B</bold>, Comparisons of our predictions (lines) of <italic>Hb</italic> (red) and <italic>C</italic><sub>avg</sub> (green) using the parameters above with data (symbols) from 12 Japanese patients with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e091" xlink:type="simple"/></inline-formula>&gt;1000 µM (solid circles) <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref>. In the latter patients, the mean <italic>Hb</italic><sub>0</sub>≈15 g/dL and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e092" xlink:type="simple"/></inline-formula>. We also show comparisons with independent data from 20 patients <xref ref-type="bibr" rid="pcbi.1001072-Homoncik1">[29]</xref> (open circles) with mean <italic>Hb</italic><sub>0</sub> = 15.1 g/dL. Solid lines are predictions with <italic>Hb</italic><sub>0</sub> = 15.1 g/dL and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e093" xlink:type="simple"/></inline-formula>, and the mean parameters mentioned above, and dashed lines represent standard deviations. <bold>C</bold>, <bold>D</bold>, Model predictions (lines) and experimental observations (symbols) of the reduction in <italic>Hb</italic> (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e094" xlink:type="simple"/></inline-formula>) under combination therapy as a function of <bold>C</bold>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e095" xlink:type="simple"/></inline-formula>, and <bold>D</bold>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e096" xlink:type="simple"/></inline-formula>, in 19 Japanese patients <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref>. Solid lines represent predictions with the mean parameter values above and dashed lines represent standard deviations obtained from several hundred realizations of our model predictions for different combinations of the values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e097" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e098" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e099" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e100" xlink:type="simple"/></inline-formula> generated randomly from distributions based on the best-fit parameter estimates and 95% confidence limits mentioned above.</p>
            </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.g005" xlink:type="simple"/></fig>
         <p>Interestingly, with the same parameter values, our model captures changes in <italic>Hb</italic> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e101" xlink:type="simple"/></inline-formula> from the other 12 Japanese patients, as well as an independent data set of <italic>Hb</italic> decline in another group of HCV patients undergoing combination therapy <xref ref-type="bibr" rid="pcbi.1001072-Homoncik1">[29]</xref> (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5B</xref>), validating our best-fit parameter estimates. Further, with the same parameter values, we estimate that the RBC lifespan is 38 days (95% CI: 19–55 days) in Japanese patients with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e102" xlink:type="simple"/></inline-formula>&lt;1000 µM and 33 days (95% CI: 14–53 days) in Japanese patients with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e103" xlink:type="simple"/></inline-formula>&gt;1000 µM. These estimates of the RBC lifespan are in close agreement with independent estimates, 39±13 days, from measurements of alveolar carbon monoxide <xref ref-type="bibr" rid="pcbi.1001072-Krishnan1">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Virtue1">[50]</xref>, presenting another successful test of our model. Finally, we find that our predictions of the dependence of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e104" xlink:type="simple"/></inline-formula> on <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e105" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e106" xlink:type="simple"/></inline-formula> using the same parameters above are also in agreement with observations in the Japanese patients <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref> (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5C,D</xref>). Our model thus presents a robust description of ribavirin-induced anemia in HCV patients undergoing combination therapy.</p>
      </sec>
      <sec id="s2d">
         <title>Clinical implications</title>
         <p>Our model has several clinical implications. First, it enables estimation of the threshold ribavirin exposure beyond which anemia is intolerable. Current treatment guidelines recommend a reduction of ribavirin dosage when <italic>Hb</italic> decreases below 10 g/dL. We apply our model to predict <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e107" xlink:type="simple"/></inline-formula> as a function of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e108" xlink:type="simple"/></inline-formula>. We find that on average (when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e109" xlink:type="simple"/></inline-formula> = 14.4 g/dL) <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e110" xlink:type="simple"/></inline-formula>&lt;10 g/dL when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e111" xlink:type="simple"/></inline-formula>&gt;13 µM (<xref ref-type="fig" rid="pcbi-1001072-g006">Fig. 6A</xref>). Thus, steady state plasma concentrations above 13 µM would render ribavirin therapy intolerable. While the dependence of the peak plasma concentration on dosage following a single ribavirin dose has been determined <xref ref-type="bibr" rid="pcbi.1001072-Glue1">[48]</xref>, the dependence of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e112" xlink:type="simple"/></inline-formula> on dosage remains to be established. A description of the multiple dose pharmacokinetics of ribavirin, which also remains elusive <xref ref-type="bibr" rid="pcbi.1001072-Pawlotsky1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Dixit1">[34]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Glue1">[48]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Preston1">[52]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Endres1">[53]</xref>, would establish the dosage corresponding to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e113" xlink:type="simple"/></inline-formula> of 13 µM that would render ribavirin intolerable.</p>
         <fig id="pcbi-1001072-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001072.g006</object-id><label>Figure 6</label>
            <caption>
               <title>Model predictions of threshold ribavirin exposure and requisite RBC production.</title>
               <p><bold>A</bold>, Prediction of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e114" xlink:type="simple"/></inline-formula> as a function of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e115" xlink:type="simple"/></inline-formula>. The arrow indicates the threshold <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e116" xlink:type="simple"/></inline-formula> above which <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e117" xlink:type="simple"/></inline-formula>&lt;10 g/dL. <bold>B</bold>, Predictions of the RBC production rate during therapy (black) and the production rate required to maintain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e118" xlink:type="simple"/></inline-formula> of 10 g/dL (pink) and 12 g/dL (blue) as functions of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e119" xlink:type="simple"/></inline-formula>. The arrows indicate the desired production rates when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e120" xlink:type="simple"/></inline-formula>. Parameter values employed are mentioned in <xref ref-type="table" rid="pcbi-1001072-t001">Table 1</xref>.</p>
            </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.g006" xlink:type="simple"/></fig>
         <p>Second, when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e121" xlink:type="simple"/></inline-formula> is above the threshold, our model allows estimation of the increase in RBC production, which may be achieved by administration of exogenous growth hormones such as recombinant erythropoietin, necessary to avert the currently recommended reduction of dosage. Because growth hormones also have side-effects <xref ref-type="bibr" rid="pcbi.1001072-Homoncik1">[29]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-McHutchison2">[54]</xref>, one strategy is to use them at levels just enough to increase <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e122" xlink:type="simple"/></inline-formula> to 10–12 g/dL (rather than the pretreatment level), which renders ribavirin tolerable <xref ref-type="bibr" rid="pcbi.1001072-Reddy2">[16]</xref>. We apply our model to predict the level of RBC production necessary for achieving <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e123" xlink:type="simple"/></inline-formula> of 10–12 g/dL for different values of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e124" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1001072-g006">Fig. 6B</xref>). Thus, when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e125" xlink:type="simple"/></inline-formula> = 15 µM, RBC production rates of 8.44 and 10.2 million cells s<sup>−1</sup> are necessary for ensuring <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e126" xlink:type="simple"/></inline-formula> of 10 and 12 g/dL, respectively. Increase in endogenous erythropoietin levels during therapy, also observed experimentally <xref ref-type="bibr" rid="pcbi.1001072-Balan1">[45]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Mangoni1">[55]</xref>, results in an enhanced production rate of 8.1 million cells s<sup>−1</sup>, which is 3.5-fold higher than the basal production rate (here 2.3 million cells s<sup>−1</sup> in the absence of ribavirin) but inadequate to achieve the desired <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e127" xlink:type="simple"/></inline-formula>. Hormone supplements may be employed to provide the balance of 0.34 or 2.1 million cells s<sup>−1</sup> increase in the RBC production rate to ensure <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e128" xlink:type="simple"/></inline-formula> of 10 or 12 g/dL, respectively. This deficiency in RBC production that hormone supplements must compensate increases with ribavirin exposure (<xref ref-type="fig" rid="pcbi-1001072-g006">Fig. 6B</xref>).</p>
      </sec>
   </sec>
   <sec id="s3">
      <title>Discussion</title>
      <p>The ability to enhance treatment response rates renders ribavirin central to the treatment of HCV infection. Maximizing the benefit of ribavirin to patients requires striking the right balance between its antiviral activity and its treatment-limiting side-effect, hemolytic anemia. Rational approaches to therapy optimization thus rely on quantitative descriptions of both the antiviral and the hemolytic activities of ribavirin. Extant mathematical models predict the enhancement in treatment response due to ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Dixit1">[34]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Rong2">[42]</xref>. Ribavirin-induced anemia, however, remains poorly described and limits our ability to maximize treatment response. Here, we fill this gap by constructing a model of the population dynamics of RBCs that quantitatively describes ribavirin-induced anemia. By assuming that intracellular accumulation of ribavirin enhances RBC death rate in a dose-dependent manner, our model captures several independent observations of ribavirin-induced anemia in HCV patients undergoing combination therapy. In particular, our model predicts the dynamics of the accumulation of ribavirin in RBCs and the resulting decline of <italic>Hb</italic> in patients following the onset of therapy, estimates the reduced lifespan of RBCs during therapy, and describes inter-patient variations in the severity of anemia, thus presenting a robust description of ribavirin-induced anemia, which, in conjunction with models of viral kinetics, may facilitate identification of treatment protocols that maximize the impact of ribavirin in the treatment of HCV infection.</p>
      <p>Our model has clinical implications. First, it allows estimation of the threshold ribavirin exposure beyond which ribavirin-induced anemia becomes intolerable. For instance, with model parameters that describe ribavirin-induced anemia in the patients we considered (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5</xref>), we estimate that steady state plasma ribavirin concentrations above 13 µM would render ribavirin therapy intolerable. Determining dosage levels corresponding to this steady state plasma concentration requires knowledge of the pharmacokinetics of ribavirin, which is currently lacking <xref ref-type="bibr" rid="pcbi.1001072-Pawlotsky1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Dixit1">[34]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Glue1">[48]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Preston1">[52]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Endres1">[53]</xref>. Ribavirin pharmacokinetics is peculiar because of an unusually long elimination phase that follows rapid absorption and distribution phases upon oral dosing <xref ref-type="bibr" rid="pcbi.1001072-Glue1">[48]</xref>. Standard absorption-elimination models of drug pharmacokinetics are unable to describe this long elimination phase. Models that include additional compartments have been proposed to capture the three-phase pharmacokinetics of ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Preston1">[52]</xref>, but the biological origin of these compartments remains unclear. An additional complication is that the half-life of the elimination phase increases from 79 h following a single dose to 274–298 h following multiple dosing <xref ref-type="bibr" rid="pcbi.1001072-Glue1">[48]</xref>, suggesting that parameters that describe single dose pharmacokinetics may not apply to multiple dose pharmacokinetics. In the absence of rigorous models of ribavirin pharmacokinetics, one may have to rely on empirical relationships between the dosage and the resulting steady state plasma concentration following multiple dosing (e.g., <xref ref-type="bibr" rid="pcbi.1001072-Glue2">[56]</xref>) to establish the dosage that would ensure tolerability of ribavirin while maximizing treatment response.</p>
      <p>Second, our model suggests guidelines for the usage of hormone supplements, such as erythropoietin, which enhance RBC production and improve the tolerability of ribavirin. For instance, we predict that when ribavirin accumulates to a plasma concentration of 15 µM, the associated enhanced RBC death rate elicits a natural response that increases RBC production 3.5-fold, from 2.3 to 8.1 million cells s<sup>−1</sup>. This response, however, is inadequate to suppress ribavirin-induced anemia adequately and renders ribavirin intolerable. We estimate then that growth hormone supplements must increase RBC production rate by an additional 0.34–2.1 million cells s<sup>−1</sup> to render ribavirin tolerable. This compensation that hormone supplements must provide increases with ribavirin accumulation. Identifying the dosage of the growth hormones that induces the necessary RBC production requires knowledge of the dose-response relationships and of the pharmacokinetics of the growth hormones, which are yet to be fully elucidated <xref ref-type="bibr" rid="pcbi.1001072-Dieterich1">[26]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Falasca1">[31]</xref>.</p>
      <p>Third, genetic variations that resulted in a deficiency in the enzyme inosine triphosphatase (ITPA) were recently found to protect HCV patients against ribavirin-induced anemia <xref ref-type="bibr" rid="pcbi.1001072-Fellay1">[51]</xref>. Deficiency in ITPA causes an increase in inosine triphosphate levels in RBCs, which is thought to interfere with RTP activity and thereby suppress the hemolytic potential of ribavirin. Because deficiency in ITPA is a clinically benign condition, therapeutic intervention to suppress ITPA presents a promising new strategy to curtail ribavirin-induced anemia without compromising the antiviral activity of ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Fellay1">[51]</xref>. Our model may be adapted to inform the development of such an intervention strategy. In our model, the dependence of the death rate of RBCs on ribavirin accumulation, determined by Eq. (2) (<xref ref-type="sec" rid="s4">Methods</xref>), would now be a function of the ITPA level. Thus, experiments that determine how variations in the ITPA level both in the absence and in the presence of ribavirin influence RBC lifespan would provide the necessary inputs for our model to account explicitly for the role of ITPA in ribavirin-induced anemia. The resulting model would enable determination of the minimal inhibition of ITPA necessary to maintain ribavirin-induced anemia within tolerable limits. Conversely, using information of the ITPA level intrinsic to a patient, the model can be applied to predict the maximum ribavirin dosage that the patient can tolerate, thus presenting an avenue for personalizing the treatment of HCV infection.</p>
   </sec>
   <sec id="s4" sec-type="methods">
      <title>Methods</title>
      <sec id="s4a">
         <title>Model development</title>
         <p>We consider the RBC population in an individual at time <italic>t</italic> following the onset of treatment with ribavirin (<italic>t</italic> = 0) (<xref ref-type="fig" rid="pcbi-1001072-g001">Fig. 1</xref>). RBCs produced at different times in the interval from 0 to <italic>t</italic> will have been exposed to ribavirin for different durations and accordingly have different intracellular levels of ribavirin. We define <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e129" xlink:type="simple"/></inline-formula> as the population of RBCs that contain ribavirin phosphorylated analogs, RXP, which comprises RMP, RDP, and RTP, at concentrations between <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e130" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e131" xlink:type="simple"/></inline-formula> at time <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e132" xlink:type="simple"/></inline-formula>. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e133" xlink:type="simple"/></inline-formula> is thus the number density of RBCs containing RXP at concentration <italic>C</italic> at time <italic>t</italic>. The time evolution of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e134" xlink:type="simple"/></inline-formula> is governed by the following equation (<xref ref-type="supplementary-material" rid="pcbi.1001072.s005">Text S1</xref>)<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e135" xlink:type="simple"/><label>(1)</label></disp-formula></p>
         <p>The first term on the right-hand-side in Eq. (1) represents the change in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e136" xlink:type="simple"/></inline-formula> due to intracellular phosphorylation of ribavirin. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e137" xlink:type="simple"/></inline-formula> is the net rate of increase of <italic>C</italic> due to phosphorylation, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e138" xlink:type="simple"/></inline-formula> is the intracellular concentration of (unphosphorylated) ribavirin, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e139" xlink:type="simple"/></inline-formula> is the phosphorylation rate and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e140" xlink:type="simple"/></inline-formula> is the rate of loss, including by possible slow dephosphorylation, of RXP. In vitro studies of ribavirin uptake by RBCs observe rapid (&lt;10 min) equilibration of intracellular and extracellular ribavirin <xref ref-type="bibr" rid="pcbi.1001072-Endres1">[53]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Jarvis1">[57]</xref>. We assume therefore that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e141" xlink:type="simple"/></inline-formula>, the concentration of ribavirin in plasma. With twice daily oral administration of ribavirin, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e142" xlink:type="simple"/></inline-formula> rises from zero at <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e143" xlink:type="simple"/></inline-formula> and reaches an asymptotic maximum, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e144" xlink:type="simple"/></inline-formula>, so that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e145" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e146" xlink:type="simple"/></inline-formula> is the characteristic timescale of the accumulation of ribavirin in plasma <xref ref-type="bibr" rid="pcbi.1001072-Pawlotsky1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Dixit2">[38]</xref>.</p>
         <p>The second term on the right-hand side of Eq. (1) accounts for the loss of RBCs due to their death. We assume that the death rate, <italic>D</italic>, of RBCs increases with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e147" xlink:type="simple"/></inline-formula> as follows<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e148" xlink:type="simple"/><label>(2)</label></disp-formula>where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e149" xlink:type="simple"/></inline-formula> is the death rate of RBCs in the absence of ribavirin, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e150" xlink:type="simple"/></inline-formula> is that value of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e151" xlink:type="simple"/></inline-formula> at which the death rate doubles (or the lifespan halves) compared to that in the absence of ribavirin, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e152" xlink:type="simple"/></inline-formula>, analogous to the Hill coefficient, determines the sensitivity of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e153" xlink:type="simple"/></inline-formula> to changes in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e154" xlink:type="simple"/></inline-formula>. (A saturable form for <italic>D</italic>(<italic>C</italic>) appears inconsistent with available data; see <xref ref-type="supplementary-material" rid="pcbi.1001072.s006">Text S2</xref>, <xref ref-type="supplementary-material" rid="pcbi.1001072.s001">Fig. S1</xref>.)</p>
         <p>Equation (1) is constrained by the initial condition that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e155" xlink:type="simple"/></inline-formula> in all cells at the start of therapy, so that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e156" xlink:type="simple"/></inline-formula>, where <italic>N</italic><sub>0</sub> is the population of RBCs at <italic>t</italic> = 0, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e157" xlink:type="simple"/></inline-formula> is the Dirac delta function, which satisfies <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e158" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e159" xlink:type="simple"/></inline-formula>. In other words, the Dirac delta function ensures that no cells have RXP at non-zero concentrations at <italic>t</italic> = 0. A second constraint on Eq. (1) is imposed by the boundary condition that when <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e160" xlink:type="simple"/></inline-formula>&gt;0, newborn cells contain no RXP so that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e161" xlink:type="simple"/></inline-formula> (<xref ref-type="supplementary-material" rid="pcbi.1001072.s005">Text S1</xref>) where<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e162" xlink:type="simple"/><label>(3)</label></disp-formula>is the rate of production of RBCs at time <italic>t</italic>.</p>
         <p>The production of RBCs by the bone marrow is regulated by a negative feedback mechanism involving the hormone erythropoietin <xref ref-type="bibr" rid="pcbi.1001072-Spivak1">[58]</xref>. Recent studies on modeling erythropoiesis elucidate the complexities involved in a quantitative description of this feedback mechanism <xref ref-type="bibr" rid="pcbi.1001072-Mahaffy1">[59]</xref>–<xref ref-type="bibr" rid="pcbi.1001072-Savill1">[65]</xref>. Here, we employ Eq. (3) to capture the essential features of this negative feedback: As the population of RBCs, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e163" xlink:type="simple"/></inline-formula>, decreases, <italic>P</italic> increases. <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e164" xlink:type="simple"/></inline-formula> is the maximum production rate of RBCs, which occurs when <italic>N</italic> is vanishingly small, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e165" xlink:type="simple"/></inline-formula> is that value of the RBC population per unit volume of blood (<inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e166" xlink:type="simple"/></inline-formula>) at which <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e167" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e168" xlink:type="simple"/></inline-formula> is the volume of blood, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e169" xlink:type="simple"/></inline-formula>, analogous to the Hill coefficient, determines the sensitivity of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e170" xlink:type="simple"/></inline-formula> to changes in <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e171" xlink:type="simple"/></inline-formula>. Eq. (3) provides good fits to independent measurements of the dynamics of the recovery of RBCs following phlebotomy (<xref ref-type="supplementary-material" rid="pcbi.1001072.s007">Text S3</xref>, <xref ref-type="supplementary-material" rid="pcbi.1001072.s002">Fig. S2</xref>).</p>
         <p>Equations (1)–(3) present a model of the population dynamics of RBCs in individuals undergoing treatment with ribavirin. We solve the equations (see below) and obtain the population density, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e172" xlink:type="simple"/></inline-formula>, and the corresponding cumulative population, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e173" xlink:type="simple"/></inline-formula>, using which we predict the time-evolution of the hemoglobin level in blood, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e174" xlink:type="simple"/></inline-formula> (where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e175" xlink:type="simple"/></inline-formula> is the volume of a single erythrocyte); the average concentration of ribavirin in RBCs, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e176" xlink:type="simple"/></inline-formula>; and the average RBC lifespan, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e177" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e178" xlink:type="simple"/></inline-formula> is the average death rate of RBCs.</p>
      </sec>
      <sec id="s4b">
         <title>Solution of model equations using the method of characteristics</title>
         <p>Equation (1) along with the initial and boundary conditions is equivalent to the following set of differential equations obtained using the method of characteristics (<xref ref-type="supplementary-material" rid="pcbi.1001072.s008">Text S4</xref>)<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e179" xlink:type="simple"/><label>(4)</label></disp-formula>where <italic>S<sub>i</sub></italic>(<italic>t</italic>) is the subpopulation of cells born within an interval <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e180" xlink:type="simple"/></inline-formula> of <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e181" xlink:type="simple"/></inline-formula> that survive at time <italic>t</italic>. <italic>C<sub>i</sub></italic>(<italic>t</italic>) is the concentration of RXP in the latter cells at time <italic>t</italic>. We solve Eq. (4) along with Eqs. (2) and (3) with <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e182" xlink:type="simple"/></inline-formula> d using a program written in MATLAB (<xref ref-type="supplementary-material" rid="pcbi.1001072.s009">Text S5</xref>). We validate our solution methodology against an analytical solution that can be obtained in the limiting case when the RBC death rate is independent of RXP accumulation (<xref ref-type="supplementary-material" rid="pcbi.1001072.s010">Text S6</xref>, <xref ref-type="supplementary-material" rid="pcbi.1001072.s003">Fig. S3</xref>). We also ensure that <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e183" xlink:type="simple"/></inline-formula> d allows accurate integration of Eq. (4) without compromising computational efficiency (<xref ref-type="supplementary-material" rid="pcbi.1001072.s004">Fig. S4</xref>). From the solution, we calculate the quantities of interest, viz., <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e184" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e185" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e186" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e187" xlink:type="simple"/></inline-formula>.</p>
      </sec>
      <sec id="s4c">
         <title>Model parameters</title>
         <p>We employ the following values of the model parameters unless stated otherwise. The average RBC lifespan in normal man is ∼120 days <xref ref-type="bibr" rid="pcbi.1001072-Krishnan1">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Berk1">[66]</xref>, which corresponds to <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e188" xlink:type="simple"/></inline-formula> d<sup>−1</sup>. We let <italic>b</italic> = 7 following earlier studies <xref ref-type="bibr" rid="pcbi.1001072-Mahaffy1">[59]</xref> and obtain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e189" xlink:type="simple"/></inline-formula> cells d<sup>−1</sup> from an independent analysis of blood loss experiments (<xref ref-type="supplementary-material" rid="pcbi.1001072.s007">Text S3</xref>). We fix <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e190" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e191" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1001072-Beck1">[67]</xref>. Using <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e192" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref>, we get <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e193" xlink:type="simple"/></inline-formula>. We obtain <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e194" xlink:type="simple"/></inline-formula> from the initial steady state <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e195" xlink:type="simple"/></inline-formula>. Further, we let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e196" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref> and because ribavirin accumulates in plasma to its maximum concentration in ∼4 weeks, we set <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e197" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1001072-Pawlotsky1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Dixit2">[38]</xref>. The remaining parameter values <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e198" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e199" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e200" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e201" xlink:type="simple"/></inline-formula> are obtained from best-fits of our model predictions to experimental data (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5A</xref>). We summarize model parameters and their values in <xref ref-type="table" rid="pcbi-1001072-t001">Table 1</xref>.</p>
         <table-wrap id="pcbi-1001072-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001072.t001</object-id><label>Table 1</label><caption>
               <title>Summary of model parameters and their values employed.</title>
            </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001072-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.t001" xlink:type="simple"/><table>
               <colgroup span="1">
                  <col align="left" span="1"/>
                  <col align="center" span="1"/>
                  <col align="center" span="1"/>
                  <col align="center" span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <td align="left" colspan="1" rowspan="1">Parameter</td>
                     <td align="left" colspan="1" rowspan="1">Description</td>
                     <td align="left" colspan="1" rowspan="1">Value (95% CI)<xref ref-type="table-fn" rid="nt101">a</xref></td>
                     <td align="left" colspan="1" rowspan="1">Source</td>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>V</italic></td>
                     <td align="left" colspan="1" rowspan="1">Volume of blood</td>
                     <td align="left" colspan="1" rowspan="1">5 L</td>
                     <td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1001072-Beck1">[67]</xref></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>v<sub>e</sub></italic></td>
                     <td align="left" colspan="1" rowspan="1">Volume of one RBC</td>
                     <td align="left" colspan="1" rowspan="1">9×10<sup>−14</sup> L</td>
                     <td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1001072-Beck1">[67]</xref></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>t<sub>a</sub></italic></td>
                     <td align="left" colspan="1" rowspan="1">Characteristic timescale of accumulation of RBV in plasma</td>
                     <td align="left" colspan="1" rowspan="1">5.4 d</td>
                     <td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1001072-Pawlotsky1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Dixit2">[38]</xref></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>b</italic></td>
                     <td align="left" colspan="1" rowspan="1">Coefficient determining sensitivity of RBC production rate to changes in number per volume of RBCs</td>
                     <td align="left" colspan="1" rowspan="1">7</td>
                     <td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1001072-Mahaffy1">[59]</xref></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>D</italic><sub>0</sub></td>
                     <td align="left" colspan="1" rowspan="1">Death rate of RBCs in the absence of ribavirin</td>
                     <td align="left" colspan="1" rowspan="1">8.3×10<sup>−3</sup> d<sup>−1</sup></td>
                     <td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1001072-Krishnan1">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1001072-Berk1">[66]</xref></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>Hb</italic><sub>0</sub></td>
                     <td align="left" colspan="1" rowspan="1">Initial Hb level</td>
                     <td align="left" colspan="1" rowspan="1">14.4 g/dL</td>
                     <td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e202" xlink:type="simple"/></inline-formula></td>
                     <td align="left" colspan="1" rowspan="1">Steady state plasma RBV concentration</td>
                     <td align="left" colspan="1" rowspan="1">7.5 µM</td>
                     <td align="left" colspan="1" rowspan="1"><xref ref-type="bibr" rid="pcbi.1001072-Inoue1">[47]</xref></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e203" xlink:type="simple"/></inline-formula></td>
                     <td align="left" colspan="1" rowspan="1">RBC population per unit volume at which RBC production rate is half maximal</td>
                     <td align="left" colspan="1" rowspan="1"/>
                     <td align="left" colspan="1" rowspan="1">Determined from pretreatment steady state, <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1001072.e204" xlink:type="simple"/></inline-formula></td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>P<sub>max</sub></italic></td>
                     <td align="left" colspan="1" rowspan="1">Maximum production rate of RBCs</td>
                     <td align="left" colspan="1" rowspan="1">8.4×10<sup>12</sup> cells d<sup>−1</sup></td>
                     <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="supplementary-material" rid="pcbi.1001072.s007">Text S3</xref>)</td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>k<sub>p</sub></italic></td>
                     <td align="left" colspan="1" rowspan="1">Phosphorylation rate of ribavirin in RBCs</td>
                     <td align="left" colspan="1" rowspan="1">65 (47–84) d<sup>−1</sup></td>
                     <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5A</xref>)</td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>k<sub>d</sub></italic></td>
                     <td align="left" colspan="1" rowspan="1">Loss rate of ribavirin phosphorylated analogs in RBCs</td>
                     <td align="left" colspan="1" rowspan="1">0.5 (0.3–0.7) d<sup>−1</sup></td>
                     <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5A</xref>)</td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>C</italic><sub>50</sub></td>
                     <td align="left" colspan="1" rowspan="1">Concentration of ribavirin phosphorylated analogs at which RBC death rate is twice the pretreatment value</td>
                     <td align="left" colspan="1" rowspan="1">408 (189–628) µM</td>
                     <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5A</xref>)</td>
                  </tr>
                  <tr>
                     <td align="left" colspan="1" rowspan="1"><italic>γ</italic></td>
                     <td align="left" colspan="1" rowspan="1">Coefficient determining sensitivity of RBC death rate to changes in concentration of ribavirin phosphorylated analogs</td>
                     <td align="left" colspan="1" rowspan="1">1 (0.2–1.8)</td>
                     <td align="left" colspan="1" rowspan="1">Best-fit (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5A</xref>)</td>
                  </tr>
               </tbody>
            </table></alternatives><table-wrap-foot>
               <fn id="nt101">
                  <label>a</label>
                  <p>Typical values employed. Variations are indicated in the text and in figure legends.</p>
               </fn>
            </table-wrap-foot></table-wrap>
      </sec>
      <sec id="s4d">
         <title>Fits of model predictions to patient data</title>
         <p>We fit model predictions to experimental data (<xref ref-type="fig" rid="pcbi-1001072-g005">Fig. 5A</xref>) using the nonlinear regression tool NLINFIT in MATLAB.</p>
      </sec>
   </sec>
   <sec id="s5">
      <title>Supporting Information</title>
<supplementary-material id="pcbi.1001072.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s001" xlink:type="simple">
<label>Figure S1</label>
<caption><p>Hemoglobin reduction as a function of the intracellular ribavirin concentration.</p>
      <p>(0.09 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s002" xlink:type="simple">
<label>Figure S2</label>
<caption><p>Analysis of RBC recovery following phlebotomy.</p>
      <p>(0.41 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s003" xlink:type="simple">
<label>Figure S3</label>
<caption><p>Validation of the solution methodology.</p>
      <p>(0.39 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s004" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s004" xlink:type="simple">
<label>Figure S4</label>
<caption><p>Sensitivity of the numerical solution to the integration time step.</p>
      <p>(0.37 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s005" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s005" xlink:type="simple">
<label>Text S1</label>
<caption><p>Derivation of equation (1) and its boundary condition.</p>
      <p>(0.29 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s006" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s006" xlink:type="simple">
<label>Text S2</label>
<caption><p>Dependence of RBC death rate on intracellular ribavirin concentration.</p>
      <p>(0.19 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s007" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s007" xlink:type="simple">
<label>Text S3</label>
<caption><p>Analysis of phlebotomy experiments.</p>
      <p>(0.28 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s008" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s008" xlink:type="simple">
<label>Text S4</label>
<caption><p>Solution of model equations using the method of characteristics.</p>
      <p>(0.30 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s009" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s009" xlink:type="simple">
<label>Text S5</label>
<caption><p>MATLAB program for solving model equations.</p>
      <p>(0.19 MB PDF)</p></caption></supplementary-material>
<supplementary-material id="pcbi.1001072.s010" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001072.s010" xlink:type="simple">
<label>Text S6</label>
<caption><p>Validation of the solution methodology.</p>
      <p>(0.20 MB PDF)</p></caption></supplementary-material>
   </sec>
</body>
<back>
   <ack>
      <p>We thank Alan S. Perelson and Ruy M. Ribeiro for helpful comments.</p>
   </ack>
   <ref-list>
      <title>References</title>
      <ref id="pcbi.1001072-Lavanchy1">
         <label>1</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Lavanchy</surname><given-names>D</given-names></name>
            </person-group>
            <year>2009</year>
            <article-title>The global burden of hepatitis C.</article-title>
            <source>Liver Int</source>
            <volume>29</volume>
            <fpage>74</fpage>
            <lpage>81</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Ghany1">
         <label>2</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Ghany</surname><given-names>MG</given-names></name>
               <name name-style="western"><surname>Strader</surname><given-names>DB</given-names></name>
               <name name-style="western"><surname>Thomas</surname><given-names>DL</given-names></name>
               <name name-style="western"><surname>Seeff</surname><given-names>LB</given-names></name>
            </person-group>
            <year>2009</year>
            <article-title>Diagnosis, management, and treatment of hepatitis C: An update.</article-title>
            <source>Hepatology</source>
            <volume>49</volume>
            <fpage>1335</fpage>
            <lpage>1374</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Dusheiko1">
         <label>3</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Dusheiko</surname><given-names>G</given-names></name>
               <name name-style="western"><surname>Main</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Thomas</surname><given-names>H</given-names></name>
               <name name-style="western"><surname>Reichard</surname><given-names>O</given-names></name>
               <name name-style="western"><surname>Lee</surname><given-names>C</given-names></name>
               <etal/>
            </person-group>
            <year>1996</year>
            <article-title>Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.</article-title>
            <source>J Hepatol</source>
            <volume>25</volume>
            <fpage>591</fpage>
            <lpage>598</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Bodenheimer1">
         <label>4</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Bodenheimer</surname><given-names>HC</given-names></name>
               <name name-style="western"><surname>Lindsay</surname><given-names>KL</given-names></name>
               <name name-style="western"><surname>Davis</surname><given-names>GL</given-names></name>
               <name name-style="western"><surname>Lewis</surname><given-names>JH</given-names></name>
               <name name-style="western"><surname>Thung</surname><given-names>SN</given-names></name>
               <etal/>
            </person-group>
            <year>1997</year>
            <article-title>Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial.</article-title>
            <source>Hepatology</source>
            <volume>26</volume>
            <fpage>473</fpage>
            <lpage>477</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Zoulim1">
         <label>5</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Zoulim</surname><given-names>F</given-names></name>
               <name name-style="western"><surname>Haem</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Ahmed</surname><given-names>SS</given-names></name>
               <name name-style="western"><surname>Chossegros</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Habersetzer</surname><given-names>F</given-names></name>
               <etal/>
            </person-group>
            <year>1998</year>
            <article-title>Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.</article-title>
            <source>J Viral Hepat</source>
            <volume>5</volume>
            <fpage>193</fpage>
            <lpage>198</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Pawlotsky1">
         <label>6</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Pawlotsky</surname><given-names>JM</given-names></name>
               <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>
               <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>
               <name name-style="western"><surname>Hezode</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Germanidis</surname><given-names>G</given-names></name>
               <etal/>
            </person-group>
            <year>2004</year>
            <article-title>Antiviral action of ribavirin in chronic hepatitis C.</article-title>
            <source>Gastroenterology</source>
            <volume>126</volume>
            <fpage>703</fpage>
            <lpage>714</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Manns1">
         <label>7</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Manns</surname><given-names>MP</given-names></name>
               <name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name>
               <name name-style="western"><surname>Gordon</surname><given-names>SC</given-names></name>
               <name name-style="western"><surname>Rustgi</surname><given-names>VK</given-names></name>
               <name name-style="western"><surname>Shiffman</surname><given-names>M</given-names></name>
               <etal/>
            </person-group>
            <year>2001</year>
            <article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.</article-title>
            <source>Lancet</source>
            <volume>358</volume>
            <fpage>958</fpage>
            <lpage>965</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Fried1">
         <label>8</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Fried</surname><given-names>MW</given-names></name>
               <name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>
               <name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
               <name name-style="western"><surname>Smith</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Marinos</surname><given-names>G</given-names></name>
               <etal/>
            </person-group>
            <year>2002</year>
            <article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.</article-title>
            <source>N Engl J Med</source>
            <volume>347</volume>
            <fpage>975</fpage>
            <lpage>982</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-McHutchison1">
         <label>9</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name>
               <name name-style="western"><surname>Gordon</surname><given-names>SC</given-names></name>
               <name name-style="western"><surname>Schiff</surname><given-names>ER</given-names></name>
               <name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>
               <name name-style="western"><surname>Lee</surname><given-names>WM</given-names></name>
               <etal/>
            </person-group>
            <year>1998</year>
            <article-title>Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.</article-title>
            <source>N Engl J Med</source>
            <volume>339</volume>
            <fpage>1485</fpage>
            <lpage>1492</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Reichard1">
         <label>10</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Reichard</surname><given-names>O</given-names></name>
               <name name-style="western"><surname>Norkrans</surname><given-names>G</given-names></name>
               <name name-style="western"><surname>Fryden</surname><given-names>A</given-names></name>
               <name name-style="western"><surname>Braconier</surname><given-names>JH</given-names></name>
               <name name-style="western"><surname>Sonnerborg</surname><given-names>A</given-names></name>
               <etal/>
            </person-group>
            <year>1998</year>
            <article-title>Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C.</article-title>
            <source>Lancet</source>
            <volume>351</volume>
            <fpage>83</fpage>
            <lpage>87</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Poynard1">
         <label>11</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Poynard</surname><given-names>T</given-names></name>
               <name name-style="western"><surname>Marcellin</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Lee</surname><given-names>SS</given-names></name>
               <name name-style="western"><surname>Niederau</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Minuk</surname><given-names>GS</given-names></name>
               <etal/>
            </person-group>
            <year>1998</year>
            <article-title>Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.</article-title>
            <source>Lancet</source>
            <volume>352</volume>
            <fpage>1426</fpage>
            <lpage>1432</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Franceschi1">
         <label>12</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Franceschi</surname><given-names>LD</given-names></name>
               <name name-style="western"><surname>Fattovich</surname><given-names>G</given-names></name>
               <name name-style="western"><surname>Turrini</surname><given-names>F</given-names></name>
               <name name-style="western"><surname>Brugnara</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Manzato</surname><given-names>F</given-names></name>
               <etal/>
            </person-group>
            <year>2000</year>
            <article-title>Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage.</article-title>
            <source>Hepatology</source>
            <volume>31</volume>
            <fpage>997</fpage>
            <lpage>1004</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Sulkowski1">
         <label>13</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Sulkowski</surname><given-names>MS</given-names></name>
            </person-group>
            <year>2003</year>
            <article-title>Anemia in the treatment of hepatitis C virus Infection.</article-title>
            <source>Clin Infect Dis</source>
            <volume>37</volume>
            <fpage>s315</fpage>
            <lpage>322</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Reddy1">
         <label>14</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
               <name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>
               <name name-style="western"><surname>Morgan</surname><given-names>TR</given-names></name>
               <name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name>
               <name name-style="western"><surname>Hadziyannis</surname><given-names>S</given-names></name>
               <etal/>
            </person-group>
            <year>2007</year>
            <article-title>Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <volume>5</volume>
            <fpage>124</fpage>
            <lpage>129</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Sulkowski2">
         <label>15</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Sulkowski</surname><given-names>MS</given-names></name>
               <name name-style="western"><surname>Wasserman</surname><given-names>R</given-names></name>
               <name name-style="western"><surname>Brooks</surname><given-names>L</given-names></name>
               <name name-style="western"><surname>Ball</surname><given-names>L</given-names></name>
               <name name-style="western"><surname>Gish</surname><given-names>R</given-names></name>
            </person-group>
            <year>2004</year>
            <article-title>Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.</article-title>
            <source>J Viral Hepat</source>
            <volume>11</volume>
            <fpage>243</fpage>
            <lpage>250</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Reddy2">
         <label>16</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
               <name name-style="western"><surname>Nelson</surname><given-names>DR</given-names></name>
               <name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name>
            </person-group>
            <year>2009</year>
            <article-title>Ribavirin: Current role in the optimal clinical management of chronic hepatitis C.</article-title>
            <source>J Hepatol</source>
            <volume>50</volume>
            <fpage>402</fpage>
            <lpage>411</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Hazode1">
         <label>17</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Hazode</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Forestier</surname><given-names>N</given-names></name>
               <name name-style="western"><surname>Dusheiko</surname><given-names>G</given-names></name>
               <name name-style="western"><surname>Ferenci</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Pol</surname><given-names>S</given-names></name>
               <etal/>
            </person-group>
            <year>2009</year>
            <article-title>Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.</article-title>
            <source>N Engl J Med</source>
            <volume>360</volume>
            <fpage>1839</fpage>
            <lpage>1850</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Lemon1">
         <label>18</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Lemon</surname><given-names>SM</given-names></name>
               <name name-style="western"><surname>McKeating</surname><given-names>JA</given-names></name>
               <name name-style="western"><surname>Pietschmann</surname><given-names>T</given-names></name>
               <name name-style="western"><surname>Frick</surname><given-names>DN</given-names></name>
               <name name-style="western"><surname>Glenn</surname><given-names>JS</given-names></name>
               <etal/>
            </person-group>
            <year>2010</year>
            <article-title>Development of novel therapies for hepatitis C.</article-title>
            <source>Antivir Res</source>
            <volume>86</volume>
            <fpage>79</fpage>
            <lpage>92</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Zeuzem1">
         <label>19</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name>
            </person-group>
            <year>2008</year>
            <article-title>Interferon-based therapy for chronic hepatitis C: current and future perspectives.</article-title>
            <source>Nat Clin Pract Gastroenterol Hepatol</source>
            <volume>5</volume>
            <fpage>610</fpage>
            <lpage>622</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Jain1">
         <label>20</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Jain</surname><given-names>MK</given-names></name>
               <name name-style="western"><surname>Zoellner</surname><given-names>C</given-names></name>
            </person-group>
            <year>2010</year>
            <article-title>Role of ribavirin in HCV treatment response: now and in the future.</article-title>
            <source>Expert Opin Pharmaco</source>
            <volume>11</volume>
            <fpage>673</fpage>
            <lpage>683</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Landaverde1">
         <label>21</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Landaverde</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Saab</surname><given-names>S</given-names></name>
            </person-group>
            <year>2009</year>
            <article-title>Optimizing peginterferon and ribavirin administration in difficult-to-treat patient populations.</article-title>
            <source>Curr Hepatitis Rep</source>
            <volume>8</volume>
            <fpage>43</fpage>
            <lpage>51</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Morello1">
         <label>22</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Morello</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Rodriguez-Novoa</surname><given-names>S</given-names></name>
               <name name-style="western"><surname>Jimenez-Nacher</surname><given-names>I</given-names></name>
               <name name-style="western"><surname>Soriano</surname><given-names>V</given-names></name>
            </person-group>
            <year>2008</year>
            <article-title>Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.</article-title>
            <source>J Antimicrob Chemother</source>
            <volume>62</volume>
            <fpage>1174</fpage>
            <lpage>1180</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Schmid1">
         <label>23</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Schmid</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Kreil</surname><given-names>A</given-names></name>
               <name name-style="western"><surname>Jessner</surname><given-names>W</given-names></name>
               <name name-style="western"><surname>Homoncik</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Datz</surname><given-names>C</given-names></name>
               <etal/>
            </person-group>
            <year>2005</year>
            <article-title>Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens.</article-title>
            <source>Gut</source>
            <volume>54</volume>
            <fpage>1014</fpage>
            <lpage>1020</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Tod1">
         <label>24</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Tod</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Farcy-Afif</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Stocco</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Boyer</surname><given-names>N</given-names></name>
               <name name-style="western"><surname>Bouton</surname><given-names>VR</given-names></name>
               <etal/>
            </person-group>
            <year>2005</year>
            <article-title>Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.</article-title>
            <source>Clin Pharmacokinet</source>
            <volume>44</volume>
            <fpage>417</fpage>
            <lpage>428</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-DebRoy1">
         <label>25</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>DebRoy</surname><given-names>S</given-names></name>
               <name name-style="western"><surname>Kribs-Zaleta</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Mubayi</surname><given-names>A</given-names></name>
               <name name-style="western"><surname>Cardona-Meléndez</surname><given-names>GM</given-names></name>
               <name name-style="western"><surname>Medina-Rios</surname><given-names>L</given-names></name>
               <etal/>
            </person-group>
            <year>2010</year>
            <article-title>Evaluating treatment of hepatitis C for hemolytic anemia management.</article-title>
            <source>Math Biosci</source>
            <volume>225</volume>
            <fpage>141</fpage>
            <lpage>155</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Dieterich1">
         <label>26</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Dieterich</surname><given-names>DT</given-names></name>
               <name name-style="western"><surname>Wasserman</surname><given-names>R</given-names></name>
               <name name-style="western"><surname>Brau</surname><given-names>N</given-names></name>
               <name name-style="western"><surname>Hassanein</surname><given-names>TI</given-names></name>
               <name name-style="western"><surname>Bini</surname><given-names>EJ</given-names></name>
               <etal/>
            </person-group>
            <year>2003</year>
            <article-title>Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.</article-title>
            <source>Am J Gastroenterol</source>
            <volume>98</volume>
            <fpage>2491</fpage>
            <lpage>2499</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Afdhal1">
         <label>27</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Afdhal</surname><given-names>NH</given-names></name>
               <name name-style="western"><surname>Dieterich</surname><given-names>DT</given-names></name>
               <name name-style="western"><surname>Pockros</surname><given-names>PJ</given-names></name>
               <name name-style="western"><surname>Schiff</surname><given-names>ER</given-names></name>
               <name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>
               <etal/>
            </person-group>
            <year>2004</year>
            <article-title>Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.</article-title>
            <source>Gastroenterology</source>
            <volume>126</volume>
            <fpage>1302</fpage>
            <lpage>1311</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Rio1">
         <label>28</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Rio</surname><given-names>RAD</given-names></name>
               <name name-style="western"><surname>Post</surname><given-names>AB</given-names></name>
               <name name-style="western"><surname>Singer</surname><given-names>ME</given-names></name>
            </person-group>
            <year>2006</year>
            <article-title>Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.</article-title>
            <source>Hepatology</source>
            <volume>44</volume>
            <fpage>1598</fpage>
            <lpage>1606</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Homoncik1">
         <label>29</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Homoncik</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Sieghart</surname><given-names>W</given-names></name>
               <name name-style="western"><surname>Formann</surname><given-names>E</given-names></name>
               <name name-style="western"><surname>Schmid</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Ferenci</surname><given-names>P</given-names></name>
               <etal/>
            </person-group>
            <year>2006</year>
            <article-title>Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.</article-title>
            <source>Amer J Gastroenterol</source>
            <volume>101</volume>
            <fpage>2275</fpage>
            <lpage>2282</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Shiffman1">
         <label>30</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>
               <name name-style="western"><surname>Salvatore</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Hubbard</surname><given-names>S</given-names></name>
               <name name-style="western"><surname>Price</surname><given-names>A</given-names></name>
               <name name-style="western"><surname>Sterling</surname><given-names>RK</given-names></name>
               <etal/>
            </person-group>
            <year>2007</year>
            <article-title>Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.</article-title>
            <source>Hepatology</source>
            <volume>46</volume>
            <fpage>371</fpage>
            <lpage>379</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Falasca1">
         <label>31</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Falasca</surname><given-names>F</given-names></name>
               <name name-style="western"><surname>Ucciferri</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Mancino</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Gorgoretti</surname><given-names>V</given-names></name>
               <name name-style="western"><surname>Pizzigallo</surname><given-names>E</given-names></name>
               <etal/>
            </person-group>
            <year>2010</year>
            <article-title>Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.</article-title>
            <source>J Med Virol</source>
            <volume>82</volume>
            <fpage>49</fpage>
            <lpage>56</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Feld1">
         <label>32</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Feld</surname><given-names>JJ</given-names></name>
               <name name-style="western"><surname>Hoofnagle</surname><given-names>JH</given-names></name>
            </person-group>
            <year>2005</year>
            <article-title>Mechanism of action of interferon and ribavirin in treatment of hepatitis C.</article-title>
            <source>Nature</source>
            <volume>436</volume>
            <fpage>967</fpage>
            <lpage>972</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Parker1">
         <label>33</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Parker</surname><given-names>WB</given-names></name>
            </person-group>
            <year>2005</year>
            <article-title>Metabolism and antiviral activity of ribavirin.</article-title>
            <source>Virus Res</source>
            <volume>107</volume>
            <fpage>165</fpage>
            <lpage>171</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Dixit1">
         <label>34</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>
               <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
            </person-group>
            <year>2006</year>
            <article-title>The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus.</article-title>
            <source>Cell Mol Life Sci</source>
            <volume>63</volume>
            <fpage>832</fpage>
            <lpage>842</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Neumann1">
         <label>35</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Neumann</surname><given-names>AU</given-names></name>
               <name name-style="western"><surname>Lam</surname><given-names>NP</given-names></name>
               <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>
               <name name-style="western"><surname>Gretch</surname><given-names>DR</given-names></name>
               <name name-style="western"><surname>Wiley</surname><given-names>TE</given-names></name>
               <etal/>
            </person-group>
            <year>1998</year>
            <article-title>Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.</article-title>
            <source>Science</source>
            <volume>282</volume>
            <fpage>103</fpage>
            <lpage>107</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Herrmann1">
         <label>36</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Herrmann</surname><given-names>E</given-names></name>
               <name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name>
               <name name-style="western"><surname>Marinos</surname><given-names>G</given-names></name>
               <name name-style="western"><surname>Modi</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name>
            </person-group>
            <year>2003</year>
            <article-title>Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.</article-title>
            <source>Hepatology</source>
            <volume>37</volume>
            <fpage>1351</fpage>
            <lpage>1358</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Colombatto1">
         <label>37</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Colombatto</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Civitano</surname><given-names>L</given-names></name>
               <name name-style="western"><surname>Oliveri</surname><given-names>F</given-names></name>
               <name name-style="western"><surname>Coco</surname><given-names>B</given-names></name>
               <name name-style="western"><surname>Ciccorossi</surname><given-names>P</given-names></name>
               <etal/>
            </person-group>
            <year>2003</year>
            <article-title>Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.</article-title>
            <source>Antivir Ther</source>
            <volume>8</volume>
            <fpage>519</fpage>
            <lpage>530</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Dixit2">
         <label>38</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>
               <name name-style="western"><surname>Layden-Almer</surname><given-names>JE</given-names></name>
               <name name-style="western"><surname>Layden</surname><given-names>TJ</given-names></name>
               <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
            </person-group>
            <year>2004</year>
            <article-title>Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.</article-title>
            <source>Nature</source>
            <volume>432</volume>
            <fpage>922</fpage>
            <lpage>924</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Dahari1">
         <label>39</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>
               <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>
               <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
            </person-group>
            <year>2007</year>
            <article-title>Triphasic decline of hepatitis C virus RNA during antiviral therapy.</article-title>
            <source>Hepatology</source>
            <volume>46</volume>
            <fpage>16</fpage>
            <lpage>21</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Dixit3">
         <label>40</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>
            </person-group>
            <year>2008</year>
            <article-title>Advances in the mathematical modelling of hepatitis C virus dynamics.</article-title>
            <source>J Indian I Sci</source>
            <volume>88</volume>
            <fpage>37</fpage>
            <lpage>43</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Rong1">
         <label>41</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>
               <name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>
               <name name-style="western"><surname>Ribeiro</surname><given-names>RM</given-names></name>
               <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
            </person-group>
            <year>2010</year>
            <article-title>Rapid emergence of protease inhibitor resistance in hepatitis C virus.</article-title>
            <source>Sci Transl Med</source>
            <volume>2</volume>
            <fpage>30ra32</fpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Rong2">
         <label>42</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Rong</surname><given-names>L</given-names></name>
               <name name-style="western"><surname>Perelson</surname><given-names>AS</given-names></name>
            </person-group>
            <year>2010</year>
            <article-title>Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.</article-title>
            <source>Crit Rev Immunol</source>
            <volume>30</volume>
            <fpage>131</fpage>
            <lpage>148</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Vlierberghe1">
         <label>43</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Vlierberghe</surname><given-names>HV</given-names></name>
               <name name-style="western"><surname>Delanghe</surname><given-names>JR</given-names></name>
               <name name-style="western"><surname>Vos</surname><given-names>MD</given-names></name>
               <name name-style="western"><surname>Leroux-Roel</surname><given-names>G</given-names></name>
            </person-group>
            <year>2001</year>
            <article-title>Factors influencing ribavirin-induced hemolysis.</article-title>
            <source>J Hepatol</source>
            <volume>34</volume>
            <fpage>911</fpage>
            <lpage>916</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Takaki1">
         <label>44</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Takaki</surname><given-names>S</given-names></name>
               <name name-style="western"><surname>Tsubota</surname><given-names>A</given-names></name>
               <name name-style="western"><surname>Hosaka</surname><given-names>T</given-names></name>
               <name name-style="western"><surname>Akuta</surname><given-names>N</given-names></name>
               <name name-style="western"><surname>Someya</surname><given-names>T</given-names></name>
               <etal/>
            </person-group>
            <year>2004</year>
            <article-title>Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.</article-title>
            <source>J Gastroenterol</source>
            <volume>39</volume>
            <fpage>668</fpage>
            <lpage>673</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Balan1">
         <label>45</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Balan</surname><given-names>V</given-names></name>
               <name name-style="western"><surname>Schwartz</surname><given-names>D</given-names></name>
               <name name-style="western"><surname>Wu</surname><given-names>GY</given-names></name>
               <name name-style="western"><surname>Muir</surname><given-names>AJ</given-names></name>
               <name name-style="western"><surname>Ghalib</surname><given-names>R</given-names></name>
               <etal/>
            </person-group>
            <year>2005</year>
            <article-title>Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.</article-title>
            <source>Am J Gastroenterol</source>
            <volume>100</volume>
            <fpage>299</fpage>
            <lpage>307</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Donnerer1">
         <label>46</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Donnerer</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Grahovic</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Stelzl</surname><given-names>E</given-names></name>
               <name name-style="western"><surname>Kessler</surname><given-names>HH</given-names></name>
               <name name-style="western"><surname>Bankuti</surname><given-names>C</given-names></name>
               <etal/>
            </person-group>
            <year>2006</year>
            <article-title>Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.</article-title>
            <source>Pharmacology</source>
            <volume>76</volume>
            <fpage>136</fpage>
            <lpage>140</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Inoue1">
         <label>47</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Inoue</surname><given-names>Y</given-names></name>
               <name name-style="western"><surname>Hommaa</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Matsuzaki</surname><given-names>Y</given-names></name>
               <name name-style="western"><surname>Shibata</surname><given-names>M</given-names></name>
               <name name-style="western"><surname>Matsumura</surname><given-names>T</given-names></name>
               <etal/>
            </person-group>
            <year>2006</year>
            <article-title>Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy.</article-title>
            <source>Hepatol Res</source>
            <volume>34</volume>
            <fpage>23</fpage>
            <lpage>27</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Glue1">
         <label>48</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Glue</surname><given-names>P</given-names></name>
            </person-group>
            <year>1999</year>
            <article-title>The clinical pharmacology of ribavirin.</article-title>
            <source>Semin Liv Dis</source>
            <volume>19</volume>
            <fpage>17</fpage>
            <lpage>24</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Krishnan1">
         <label>49</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Krishnan</surname><given-names>SM</given-names></name>
               <name name-style="western"><surname>Dixit</surname><given-names>NM</given-names></name>
            </person-group>
            <year>2009</year>
            <article-title>Estimation of red blood cell lifespan from alveolar carbon monoxide measurements.</article-title>
            <source>Transl Res</source>
            <volume>154</volume>
            <fpage>15</fpage>
            <lpage>17</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Virtue1">
         <label>50</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Virtue</surname><given-names>MA</given-names></name>
               <name name-style="western"><surname>Furne</surname><given-names>JK</given-names></name>
               <name name-style="western"><surname>Ho</surname><given-names>SB</given-names></name>
               <name name-style="western"><surname>Levitt</surname><given-names>MD</given-names></name>
            </person-group>
            <year>2004</year>
            <article-title>Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival.</article-title>
            <source>Am J Hematol</source>
            <volume>76</volume>
            <fpage>107</fpage>
            <lpage>113</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Fellay1">
         <label>51</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Fellay</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name>
               <name name-style="western"><surname>Ge</surname><given-names>D</given-names></name>
               <name name-style="western"><surname>Gumbs</surname><given-names>CE</given-names></name>
               <name name-style="western"><surname>Urban</surname><given-names>TJ</given-names></name>
               <etal/>
            </person-group>
            <year>2010</year>
            <article-title>ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.</article-title>
            <source>Nature</source>
            <volume>464</volume>
            <fpage>405</fpage>
            <lpage>408</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Preston1">
         <label>52</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Preston</surname><given-names>SL</given-names></name>
               <name name-style="western"><surname>Drusano</surname><given-names>GL</given-names></name>
               <name name-style="western"><surname>Glue</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Nash</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Gupta</surname><given-names>SK</given-names></name>
               <etal/>
            </person-group>
            <year>1999</year>
            <article-title>Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <volume>43</volume>
            <fpage>2451</fpage>
            <lpage>2456</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Endres1">
         <label>53</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Endres</surname><given-names>CJ</given-names></name>
               <name name-style="western"><surname>Moss</surname><given-names>AM</given-names></name>
               <name name-style="western"><surname>Ke</surname><given-names>B</given-names></name>
               <name name-style="western"><surname>Govindarajan</surname><given-names>R</given-names></name>
               <name name-style="western"><surname>Choi</surname><given-names>DS</given-names></name>
               <etal/>
            </person-group>
            <year>2009</year>
            <article-title>The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <volume>329</volume>
            <fpage>387</fpage>
            <lpage>398</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-McHutchison2">
         <label>54</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name>
               <name name-style="western"><surname>Manns</surname><given-names>MP</given-names></name>
               <name name-style="western"><surname>Brown</surname><given-names>RS</given-names></name>
               <name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
               <name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>
               <etal/>
            </person-group>
            <year>2007</year>
            <article-title>Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.</article-title>
            <source>Am J Gastroenterol</source>
            <volume>102</volume>
            <fpage>880</fpage>
            <lpage>889</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Mangoni1">
         <label>55</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Mangoni</surname><given-names>ED</given-names></name>
               <name name-style="western"><surname>Marrone</surname><given-names>A</given-names></name>
               <name name-style="western"><surname>Saviano</surname><given-names>D</given-names></name>
               <name name-style="western"><surname>Del Vecchio</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Utili</surname><given-names>R</given-names></name>
               <etal/>
            </person-group>
            <year>2003</year>
            <article-title>Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anemia.</article-title>
            <source>Antivir Ther</source>
            <volume>8</volume>
            <fpage>57</fpage>
            <lpage>63</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Glue2">
         <label>56</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Glue</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Rouzier-Panis</surname><given-names>R</given-names></name>
               <name name-style="western"><surname>Raffanel</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Sabo</surname><given-names>R</given-names></name>
               <name name-style="western"><surname>Gupta</surname><given-names>SK</given-names></name>
               <etal/>
            </person-group>
            <year>2000</year>
            <article-title>A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.</article-title>
            <source>Hepatology</source>
            <volume>32</volume>
            <fpage>647</fpage>
            <lpage>653</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Jarvis1">
         <label>57</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Jarvis</surname><given-names>SM</given-names></name>
               <name name-style="western"><surname>Thorn</surname><given-names>JA</given-names></name>
               <name name-style="western"><surname>Glue</surname><given-names>P</given-names></name>
            </person-group>
            <year>1998</year>
            <article-title>Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters.</article-title>
            <source>Br J Pharmacol</source>
            <volume>123</volume>
            <fpage>1587</fpage>
            <lpage>1592</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Spivak1">
         <label>58</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Spivak</surname><given-names>JL</given-names></name>
            </person-group>
            <year>2000</year>
            <article-title>The blood in systemic disorders.</article-title>
            <source>Lancet</source>
            <volume>355</volume>
            <fpage>1707</fpage>
            <lpage>1712</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Mahaffy1">
         <label>59</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Mahaffy</surname><given-names>JM</given-names></name>
               <name name-style="western"><surname>Belair</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Mackey</surname><given-names>MC</given-names></name>
            </person-group>
            <year>1998</year>
            <article-title>Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis.</article-title>
            <source>J Theor Biol</source>
            <volume>190</volume>
            <fpage>135</fpage>
            <lpage>146</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-VengPederson1">
         <label>60</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Veng-Pederson</surname><given-names>P</given-names></name>
               <name name-style="western"><surname>Chapel</surname><given-names>S</given-names></name>
               <name name-style="western"><surname>Schmidt</surname><given-names>PRL</given-names></name>
               <name name-style="western"><surname>Al-Huniti</surname><given-names>NH</given-names></name>
               <name name-style="western"><surname>Cook</surname><given-names>RT</given-names></name>
               <etal/>
            </person-group>
            <year>2002</year>
            <article-title>An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.</article-title>
            <source>Pharm Res</source>
            <volume>19</volume>
            <fpage>1630</fpage>
            <lpage>1635</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Colijn1">
         <label>61</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Colijn</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Mackey</surname><given-names>MC</given-names></name>
            </person-group>
            <year>2005</year>
            <article-title>A mathematical model of hematopoiesis–I. Periodic chronic myelogenous leukemia.</article-title>
            <source>J Theor Biol</source>
            <volume>237</volume>
            <fpage>117</fpage>
            <lpage>132</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Roeder1">
         <label>62</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Roeder</surname><given-names>I</given-names></name>
            </person-group>
            <year>2006</year>
            <article-title>Quantitative stem cell biology: computational studies in the hematopoietic system.</article-title>
            <source>Curr Opin Hematol</source>
            <volume>13</volume>
            <fpage>222</fpage>
            <lpage>228</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Crauste1">
         <label>63</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Crauste</surname><given-names>F</given-names></name>
               <name name-style="western"><surname>Pujo-Menjouet</surname><given-names>L</given-names></name>
               <name name-style="western"><surname>Génieys</surname><given-names>S</given-names></name>
               <name name-style="western"><surname>Molina</surname><given-names>C</given-names></name>
               <name name-style="western"><surname>Gandrillon</surname><given-names>O</given-names></name>
            </person-group>
            <year>2008</year>
            <article-title>Adding self-renewal in committed erythroid progenitors improves the biological relevance of a mathematical model of erythropoiesis.</article-title>
            <source>J Theor Biol</source>
            <volume>250</volume>
            <fpage>322</fpage>
            <lpage>338</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Krzyzanski1">
         <label>64</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Krzyzanski</surname><given-names>W</given-names></name>
               <name name-style="western"><surname>Perez-Ruixo</surname><given-names>J</given-names></name>
               <name name-style="western"><surname>Vermeulen</surname><given-names>A</given-names></name>
            </person-group>
            <year>2008</year>
            <article-title>Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.</article-title>
            <source>J Pharmacokinet Phar</source>
            <volume>35</volume>
            <fpage>349</fpage>
            <lpage>377</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Savill1">
         <label>65</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Savill</surname><given-names>NJ</given-names></name>
               <name name-style="western"><surname>Chadwick</surname><given-names>W</given-names></name>
               <name name-style="western"><surname>Reece</surname><given-names>SE</given-names></name>
            </person-group>
            <year>2009</year>
            <article-title>Quantitative analysis of mechanisms that govern red blood cell age structure and dynamics during anaemia.</article-title>
            <source>PLoS Comput Biol</source>
            <volume>5</volume>
            <fpage>e1000416</fpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Berk1">
         <label>66</label>
         <element-citation publication-type="journal" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Berk</surname><given-names>PD</given-names></name>
               <name name-style="western"><surname>Berlin</surname><given-names>NI</given-names></name>
               <name name-style="western"><surname>Blaschke</surname><given-names>TF</given-names></name>
               <name name-style="western"><surname>Bloomer</surname><given-names>JR</given-names></name>
               <name name-style="western"><surname>Howe</surname><given-names>RB</given-names></name>
            </person-group>
            <year>1972</year>
            <article-title>Bilirubin production as a measure of red-cell life-span.</article-title>
            <source>J Lab Clin Med</source>
            <volume>79</volume>
            <fpage>364</fpage>
            <lpage>378</lpage>
         </element-citation>
      </ref>
      <ref id="pcbi.1001072-Beck1">
         <label>67</label>
         <element-citation publication-type="other" xlink:type="simple">
            <person-group person-group-type="author">
               <name name-style="western"><surname>Beck</surname><given-names>WS</given-names></name>
            </person-group>
            <year>1991</year>
            <article-title>Hematology.</article-title>
            <comment>MIT Press, Cambridge, Massachusetts</comment>
         </element-citation>
      </ref>
   </ref-list>
   
</back></article>